The market for drugs used to treat patients with chronic kidney disease and end-stage renal disease is under great pressure, driven by Medicare cost containment policies and FDA labeling changes related to drug safety.
ESRD Market Snapshot: The Price Has To Be Right
The market for kidney disease drugs is under pressure from Medicare cost containment policies. However, there is still room for new drugs – if they can demonstrate a cost-savings benefit.